|
|
|
|
|
|
|
|
|
|
|
06.10.26 - 03:36
|
Japan′s Shionogi to Buy U.S. Bioventure for 2 B. Dollars (Nippon)
|
|
|
Osaka, Oct. 6 (Jiji Press)--Major Japanese drugmaker Shionogi & Co. has said that it will acquire U.S. biopharmaceutical company IntraBio Inc. for 2 billion dollars as part of efforts to strengthen its rare disease drug business. Shionogi will buy all outstanding shares in the Austin, Texas-based company, according to an announcement Monday. Founded in 2015, IntraBio develops and commerci......
|
|
|
|
|
|
|
05.10.26 - 14:03
|
Shionogi Continues Rare Disease Expansion With Planned Acquisition of IntraBio Inc. (Business Wire)
|
|
|
Transaction will add AQNEURSA® (levacetylleucine) to Shionogi's expanding rare disease portfolio
AQNEURSA was approved in the United States in 2024 and the European Union in 2026 for neurological manifestations of Niemann-Pick disease type C (NPC)
Recent U.S. Food and Drug Administration (FDA) supplemental New Drug Approval for AQNEURSA makes it the first and only drug approved for the treatment of Ataxia in patients with Ataxia-Telangiectasia (A-T)
Milestone builds on strong rare disease foundation established through the acquisition of RADICAVA® (edaravone) and strengthens Shionogi's capabilities in rare disease
OSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced that its Board of Directors, at a meeting held on October 5, 2026, approved Shionogi entering into an agreement to acquire IntraBio Inc. (Head Office: Austin, TX; hereinafter “IntraBio”), a biopharmaceutical company deve...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
02.10.26 - 08:36
|
AZ & DS collaboration with Summit for Datroway (Cision)
|
|
|
02 October 2026
AstraZeneca and Daiichi Sankyo announce clinical collaboration
with Summit Therapeutics to evaluate Datroway in combination
with ivonescimab across multiple tumour types
Builds on recently announced clinical collaboration between AstraZeneca
and Summit to advance leading ADC combination strategy in cancer
AstraZeneca and Daiichi Sankyo have entered into a clinical collaboration agreement with Summit Therapeutics Inc. to evaluate Datroway (datopotamab deruxtecan) in combination with ivonescimab across multiple tumour types including lung and breast cancers. The...
|
|
|
01.10.26 - 17:48
|
Corus International Receives $6.4 Million Grant From Takeda to Reduce Climate-Related Health Risks in Nepal (Business Wire)
|
|
|
A model for private sector–nonprofit collaboration in tackling life-threatening health risksWASHINGTON & TOKYO--(BUSINESS WIRE)--Corus International announced it has received a $6.4 million grant from Takeda Pharmaceutical Company Limited to help reduce climate-related health risks in Nepal. Corus was selected as part of Takeda's 2026 Global Corporate Social Responsibility (CSR) program. The company issued a press release announcing all the awardees and the scope of its program.
Corus is a leading global non-governmental humanitarian assistance and development organization based in Washington, D.C. The grant provides Corus with five years of support for a first-of-its-kind initiative to help communities in Nepal anticipate and respond to climate-related health threats before they become crises.
Corus International President and CEO Ambassador Daniel Speckhard said, “This innovative program shows what's possible when the private sector and nonprofits come together to solve some of the world's most c...
|
|
|
01.10.26 - 14:01
|
SpyGlass Pharma Acquires Advanced Vision Science, Inc. (AVS), Securing Scalable Commercial IOL Supply and Accelerating Lens Portfolio Expansion Capability (GlobeNewswire EN)
|
|
|
IRVINE, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”) announced today the acquisition of all the outstanding shares of common stock of Advanced Vision Science, Inc. (AVS), an ophthalmic medical device company and manufacturer of intraocular lenses (IOLs) and lens materials, for approximately $13 million in cash. This acquisition secures scalable commercial IOL manufacturing capacity for SpyGlass Pharma. AVS was a wholly owned subsidiary of Santen Pharmaceutical Co., Ltd (Santen) and is the current supplier of SpyGlass Pharma's IOL in its two Phase 3 registrational trials evaluating the BIM-IOL System....
|
|
|
01.10.26 - 12:31
|
Nxera Announces Successful Resolution of miniG Patent Infringement Action (GlobeNewswire EN)
|
|
|
Tokyo, Japan and Cambridge and London, UK, 30 September 2026 – Nxera Pharma Co., Ltd. (“Nxera Pharma” or “the Company”; TSE 4565) announces that its wholly owned subsidiary Nxera Pharma UK Limited (“Nxera”) has entered into a settlement agreement with OMass Therapeutics Limited (“OMass”) in relation to OMass' past infringement of patents EP 3 408 286 B1 and GB 2 558 968 B relating to Nxera's proprietary miniG platform technology. ...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
